Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MHRA reclassifies oral azithromycin as OTC for Chlamydia

This article was originally published in Scrip

Executive Summary

Actavisis to make a generic antibiotic that can treat Chlamydia, azithromycin, available over the counter without a prescription at UK pharmacies later this year, the country's regulator the MHRAsays. It will be the first oral antibiotic to be approved for reclassification and will be marketed under the trade name Clamelle. The pill will be available to patients aged 16 years and over if they have tested positive to the infection and have no symptoms, and for their sexual partners. The Royal Pharmaceutical Society of Great Britainwelcomed the news, pointing out that improving access to Chlamydia treatment would help curb increasing rates of infection, particularly in the under 25s.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC000107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel